Association of Hb F Level With Clinical Severity of Beta Thalassemia

Learn more about:
Related Clinical Trial
The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study Assessment of Cognitive Function, Fatigue and Health Related Quality of Life in Children With Beta Thalassemia Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) The Prevelence of IVS 1-6 (T-C) [HBB:c.92 +6 T-C] Gene Mutation in Suspected Cases of β Thalassemia in Assiut University Hospitals Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) Study on the Effect of Different Risk Factors on the Growth Parameters of Thalassemic Patients in Assiut (AUCH) The Prevelence of HBB c.93-21 G-A in β Thalassemia Patients Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) Thrombin Generation in Beta-thalassemia Major Iron Status in BTM With Blood Transfusion Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia Genetic Variants Affecting the Clinical Severity of Beta Thalassemia Association of Hb F Level With Clinical Severity of Beta Thalassemia Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients The Role of OCTA in Patients Affected by Beta Thalassemia

Brief Title

Association of Hb F Level With Clinical Severity of Beta Thalassemia

Official Title

Association of Hb F Level With Clinical Severity of Beta Thalassemia

Brief Summary

      The production of Hb F after birth is an important factor in modifying the clinical severity
      of beta thalassemia because an increased gamma-globin level will bind the additional a-globin
      and form Hb F. The objective of this project is to evaluate the association of Hb F level
      with phenotypic diversity of patients with beta thalassemia.

Study Type


Primary Outcome

Hb F level and severity of anemia


Beta Thalassemia


Hematological Phenotype Analysis

Study Arms / Comparison Groups

 beta thalassemia patients


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Diagnostic Test

Estimated Enrollment


Start Date

December 1, 2019

Completion Date

December 30, 2025

Primary Completion Date

December 30, 2024

Eligibility Criteria

        Inclusion Criteria:

          -  Diagnosed with beta-thalassemia

        Exclusion Criteria:

          -  Iron Deficiency Anemia




N/A - N/A

Accepts Healthy Volunteers



, 02061648293, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID

HbF-Beta thalassemia

Responsible Party


Study Sponsor

Nanfang Hospital of Southern Medical University


 ZhuHai Hospital

Study Sponsor

, , 

Verification Date

May 2021